The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
Recent advances in siRNA delivery mediated by lipid-based nanoparticles
Open accessAbstract
Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the treatment of broad-spectrum intractable diseases. However, its unfavorable properties such as easy degradation in the blood and negative-charge density are still a formidable barrier for clinical use. For disruption of this barrier, siRNA delivery technology has been significantly advanced in the past two decades. The approval of Patisiran (ONPATTRO™) for the treatment of transthyretin-mediated amyloidosis, the first approved siRNA drug, is a most important milestone. Since lipid-based nanoparticles (LNPs) are used in Patisiran, LNP-based siRNA delivery is now of significant interest for the development of the next siRNA formulation. In this review, we describe the design of LNPs for the improvement of siRNA properties, bioavailability, and pharmacokinetics. Recently, a number of siRNA-encapsulated LNPs were reported for the treatment of intractable diseases such as cancer, viral infection, inflammatory neurological disorder, and genetic diseases. We believe that these contributions address and will promote the development of an effective LNP-based siRNA delivery system and siRNA formulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,361
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 3×
“This electrostatic interaction induces membrane fusion via the hexagonal II structure, allowing the release of the encapsulated siRNA into the cytoplasm [15,25].”
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
ExoCarta: A Web-Based Compendium of Exosomal Cargo
Keerthikumar, S., Chisanga, D., Ariyaratne, D., Al Saffar, H., Anand, S., Zhao, K., Samuel, M., Pathan, M., Jois, M., Chilamkurti, N., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.09.019 · Cited by 1,452
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948
Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation
Webber, J., Steadman, R., Mason, M. D., Tabi, Z., & Clayton, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1722 · Cited by 852
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Therapeutic siRNA silencing in inflammatory monocytes in mice
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1989 · Cited by 839
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Cellular Uptake of Arginine-Rich Peptides: Roles for Macropinocytosis and Actin Rearrangement
Nakase, I., Niwa, M., Takeuchi, T., Sonomura, K., Kawabata, N., Koike, Y., Takehashi, M., Tanaka, S., Ueda, K., Simpson, J. C., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.010 · Cited by 752
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2005) · Nature Medicine · doi:10.1038/nm1164 · Cited by 725
Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes
Wahlgren, J., Karlson, T. D. L., Brisslert, M., Vaziri Sani, F., Telemo, E., Sunnerhagen, P., & Valadi, H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks463 · Cited by 715
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection
Côté, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C. M., Hensley, L., Li, Q., Ory, D., Chandran, K., et al. (2011) · Nature · doi:10.1038/nature10380 · Cited by 686
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Kulkarni, J. A., Darjuan, M. M., Mercer, J. E., Chen, S., van der Meel, R., Thewalt, J. L., Tam, Y. Y. C., & Cullis, P. R. (2018) · ACS Nano · doi:10.1021/acsnano.8b01516 · Cited by 663
LAULAGNIER, K., MOTTA, C., HAMDI, S., ROY, S., FAUVELLE, F., PAGEAUX, J.-F., KOBAYASHI, T., SALLES, J.-P., PERRET, B., BONNEROT, C., et al. (2004) · Biochemical Journal · doi:10.1042/bj20031594 · Cited by 647
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming
Segura, E., Nicco, C., Lombard, B., Véron, P., Raposo, G., Batteux, F., Amigorena, S., & Théry, C. (2005) · Blood · doi:10.1182/blood-2005-01-0220 · Cited by 613
Small RNA sorting: matchmaking for Argonautes
Czech, B., & Hannon, G. J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2916 · Cited by 605
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Blood-brain barrier drug targeting: the future of brain drug development.
Pardridge, W. M. (2003) · Molecular Interventions · doi:10.1124/mi.3.2.90 · Cited by 570
Weber, S., Zimmer, A., & Pardeike, J. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.08.013 · Cited by 568
Exosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics
Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R., & van der Meel, R. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00368 · Cited by 527
Towner, J. S., Rollin, P. E., Bausch, D. G., Sanchez, A., Crary, S. M., Vincent, M., Lee, W. F., Spiropoulou, C. F., Ksiazek, T. G., Lukwiya, M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.8.4330-4341.2004 · Cited by 515
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Beà, S., Valdés-Mas, R., Navarro, A., Salaverria, I., Martín-Garcia, D., Jares, P., Giné, E., Pinyol, M., Royo, C., Nadeu, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314608110 · Cited by 513
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
Zhou, X., & Huang, L. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90066-3 · Cited by 495
Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1319 · Cited by 495
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Chonn, A., Semple, S. C., & Cullis, P. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37026-7 · Cited by 460
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Müller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., Mühlen, A. Z., Meyhers, H., de Freitas, C. F., & Rühl, D. (1995) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 455
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Filion, M. C., & Phillips, N. C. (1997) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00126-0 · Cited by 428
SOLID LIPID NANOPARTICLES: A REVIEW
Ekambaram, P., Sathali, A. A. H., & Priyanka, K. (2012) · Scientific reviews and chemical communications · Cited by 403
de Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, T., & Ray, A. S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 375
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Leung, A. K. K., Hafez, I. M., Baoukina, S., Belliveau, N. M., Zhigaltsev, I. V., Afshinmanesh, E., Tieleman, D. P., Hansen, C. L., Hope, M. J., & Cullis, P. R. (2012) · The Journal of Physical Chemistry C · doi:10.1021/jp303267y · Cited by 360
Sinusoidal communication in liver fibrosis and regeneration
Marrone, G., Shah, V. H., & Gracia-Sancho, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.018 · Cited by 323
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment
Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S., Liu, J., Wei, T., Cao, W., Zou, G., & Liang, X.-J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.058 · Cited by 315
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.009 · Cited by 309
A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302641 · Cited by 307
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Wisse, E., Jacobs, F., Topal, B., Frederik, P., & De Geest, B. (2008) · Gene Therapy · doi:10.1038/gt.2008.60 · Cited by 289
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Advances in siRNA delivery in cancer therapy
Singh, A., Trivedi, P., & Jain, N. K. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1307210 · Cited by 271
Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., et al. (2007) · Cell · doi:10.1016/j.cell.2007.02.042 · Cited by 261
Huang, K.-W., Hsu, F.-F., Qiu, J. T., Chern, G.-J., Lee, Y.-A., Chang, C.-C., Huang, Y.-T., Sung, Y.-C., Chiang, C.-C., Huang, R.-L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5032 · Cited by 256
Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy
Rassu, G., Soddu, E., Posadino, A. M., Pintus, G., Sarmento, B., Giunchedi, P., & Gavini, E. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.01.031 · Cited by 239
Wang, C. Y., & Huang, L. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7851 · Cited by 239
Maurer, N., Wong, K. F., Stark, H., Louie, L., McIntosh, D., Wong, T., Scherrer, P., Semple, S. C., & Cullis, P. R. (2001) · Biophysical Journal · doi:10.1016/s0006-3495(01)76202-9 · Cited by 232
Zhou, A., Liu, C., Garner, L., Watkins, S., Smoot, J., Daniels, A., Li, Y., Carter, L., Gregg, A., Jervey, S., et al. (2020) · doi:10.1021/scimeetings.0c07113 · Cited by 227
Kumar, V., Qin, J., Jiang, Y., Duncan, R. G., Brigham, B., Fishman, S., Nair, J. K., Akinc, A., Barros, S. A., & Kasperkovitz, P. V. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.61 · Cited by 222
Barbaro, G., Scozzafava, A., Mastrolorenzo, A., & Supuran, C. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764869 · Cited by 222
Saito, H., Lund-Katz, S., & Phillips, M. C. (2004) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.05.002 · Cited by 218
Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells
Pinnaduwage, P., Schmitt, L., & Huang, L. (1989) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(89)90099-0 · Cited by 213
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 210
RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents HIV Infection in BLT Mice
Kim, S.-S., Peer, D., Kumar, P., Subramanya, S., Wu, H., Asthana, D., Habiro, K., Yang, Y.-G., Manjunath, N., Shimaoka, M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.271 · Cited by 207
Sager, H. B., Dutta, P., Dahlman, J. E., Hulsmans, M., Courties, G., Sun, Y., Heidt, T., Vinegoni, C., Borodovsky, A., Fitzgerald, K., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1435 · Cited by 205
Octaarginine-modified multifunctional envelope-type nano device for siRNA
Nakamura, Y., Kogure, K., Futaki, S., & Harashima, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.010 · Cited by 201
Bramsen, J. B., Pakula, M. M., Hansen, T. B., Bus, C., Langkjær, N., Odadzic, D., Smicius, R., Wengel, S. L., Chattopadhyaya, J., Engels, J. W., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq341 · Cited by 195
Hepatic stellate cell (vitamin A‐storing cell) and its relative – past, present and future
Senoo, H., Yoshikawa, K., Morii, M., Miura, M., Imai, K., & Mezaki, Y. (2010) · Cell Biology International · doi:10.1042/cbi20100321 · Cited by 195
Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system
Kogure, K., Akita, H., Yamada, Y., & Harashima, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.007 · Cited by 187
Basha, G., Novobrantseva, T. I., Rosin, N., Tam, Y. Y. C., Hafez, I. M., Wong, M. K., Sugo, T., Ruda, V. M., Qin, J., Klebanov, B., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.190 · Cited by 181
Sato, Y., Hashiba, K., Sasaki, K., Maeki, M., Tokeshi, M., & Harashima, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.001 · Cited by 179
Mantle cell lymphoma: evolving management strategies
Campo, E., & Rule, S. (2015) · Blood · doi:10.1182/blood-2014-05-521898 · Cited by 176
Liposomal Nanomedicines: An Emerging Field
Fenske, D. B., Chonn, A., & Cullis, P. R. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310960 · Cited by 168
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain
Rungta, R. L., Choi, H. B., Lin, P. J., Ko, R. W., Ashby, D., Nair, J., Manoharan, M., Cullis, P. R., & MacVicar, B. A. (2013) · Molecular Therapy—Nucleic Acids · doi:10.1038/mtna.2013.65 · Cited by 165 · cited 1×
“In 2013, it was reported that ionizable cationic lipid-LNP containing siRNA spread widely in the brain and showed significant knockdown of target mRNA (GRIN1, coding GluN1 subunit of NMDA [N-methyl-Daspartate] receptor) in the brain after intracortical or intracerebroventricular injection without an immune response [2…”
Martins, S., Costa-Lima, S., Carneiro, T., Cordeiro-da-Silva, A., Souto, E. B., & Ferreira, D. C. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.032 · Cited by 165
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001997 · Cited by 165
Akita, H., Kogure, K., Moriguchi, R., Nakamura, Y., Higashi, T., Nakamura, T., Serada, S., Fujimoto, M., Naka, T., & Futaki, S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.012 · Cited by 164
Wouters, K., Shiri-Sverdlov, R., van Gorp, P. J., van Bilsen, M., & Hofker, M. H. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.085 · Cited by 163
SOLID LIPID NANOPARTICLES- A REVIEW
Yadav, N., Khatak, S., & Sara, S. (2013) · Cited by 161
Parvani, J. G., Gujrati, M. D., Mack, M. A., Schiemann, W. P., & Lu, Z.-R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3485 · Cited by 159
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Exploring the Tumor Microenvironment with Nanoparticles
Miao, L., & Huang, L. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4_9 · Cited by 157
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA
Yu, Y. H., Kim, E. J., Park, D. E., Shim, G., Lee, S. B., Kim, Y. B., Kim, C., & Oh, Y. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.002 · Cited by 154
Vector-mediated drug delivery to the brain
Pardridge, W. M. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00087-8 · Cited by 146
Modulation of Membrane Fusion by Asymmetric Transbilayer Distributions of Amino Lipids
Bailey, A. L., & Cullis, P. R. (1994) · Biochemistry · doi:10.1021/bi00208a007 · Cited by 146
Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract
Ball, R. L., Bajaj, P., & Whitehead, K. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-20632-6 · Cited by 145
In Vivo Sustained Release of siRNA from Solid Lipid Nanoparticles
Lobovkina, T., Jacobson, G. B., González-González, E., Hickerson, R. P., Leake, D., Kaspar, R. L., Contag, C. H., & Zare, R. N. (2011) · ACS Nano · doi:10.1021/nn203745n · Cited by 142
Tracey, L., Pérez‐Rosado, A., Artiga, M. J., Camacho, F. I., Rodríguez, A., Martínez, N., Ruíz-Ballesteros, E., Mollejo, M., Martinez, B., Cuadros, M., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1768 · Cited by 142
Chen, D., Parayath, N. N., Ganesh, S., Wang, W., & Amiji, M. M. (2019) · Nanoscale · doi:10.1039/c9nr05788a · Cited by 141
Nanotechnology and the Treatment of HIV Infection
Parboosing, R., Maguire, G. E. M., Govender, P., & Kruger, H. G. (2012) · Viruses · doi:10.3390/v4040488 · Cited by 134
Nanostructures for the Inhibition of Viral Infections
Szunerits, S., Barras, A., Khanal, M., Pagneux, Q., & Boukherroub, R. (2015) · Molecules · doi:10.3390/molecules200814051 · Cited by 134
Dika, I. E., Lim, H. Y., Yong, W. P., Lin, C., Yoon, J., Modiano, M., Freilich, B. L., Choi, H. J., Chao, T.-Y., Kelley, R. K., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0838 · Cited by 130
Aldayel, A. M., O’Mary, H. L., Valdes, S. A., Li, X., Thakkar, S. G., Mustafa, B. E., & Cui, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.035 · Cited by 129
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
Garba, A. O., & Mousa, S. A. (2010) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s4878 · Cited by 126
Duan, W., & Li, H. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0382-x · Cited by 122
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
Warashina, S., Nakamura, T., Sato, Y., Fujiwara, Y., Hyodo, M., Hatakeyama, H., & Harashima, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.042 · Cited by 120
Conceição, M., Mendonça, L., Nóbrega, C., Gomes, C., Costa, P., Hirai, H., Moreira, J. N., Lima, M. C., Manjunath, N., & Pereira de Almeida, L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.021 · Cited by 117
Patel, M., Souto, E. B., & Singh, K. K. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.784742 · Cited by 115
Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA
Sakurai, Y., Hatakeyama, H., Sato, Y., Akita, H., Takayama, K., Kobayashi, S., Futaki, S., & Harashima, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.047 · Cited by 114
Modifications in Small Interfering RNA That Separate Immunostimulation from RNA Interference
Eberle, F., Gießler, K., Deck, C., Heeg, K. M., Peter, M. E., Richert, C., & Dalpke, A. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3229 · Cited by 113
Kusumoto, K., Akita, H., Ishitsuka, T., Matsumoto, Y., Nomoto, T., Furukawa, R., El‐Sayed, A., Hatakeyama, H., Kajimoto, K., Yamada, Y., et al. (2013) · ACS Nano · doi:10.1021/nn401317t · Cited by 109
Katakowski, J. A., Mukherjee, G., Wilner, S. E., Maier, K. E., Harrison, M. T., DiLorenzo, T. P., Levy, M., & Palliser, D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.175 · Cited by 105
Sato, Y., Matsui, H., Yamamoto, N., Sato, R., Munakata, T., Kohara, M., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.044 · Cited by 105
Andresen, T. L., Bruun, J., Larsen, T. B., Jølck, R. I., Eliasen, R., Holm, R., & Gjetting, T. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87334 · Cited by 100
Khoury, J. D., Medeiros, L. J., Rassidakis, G. Z., McDonnell, T. J., Abruzzo, L. V., & Lai, R. L. (2002) · The Journal of Pathology · doi:10.1002/path.1254 · Cited by 100
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
Jyotsana, N., Sharma, A. K., Chaturvedi, A., Budida, R., Scherr, M., Kuchenbauer, F. C., Lindner, R. M., Noyan, F., Sühs, K., Stangel, M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03713-y · Cited by 100
Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing
Gao, J., Sun, J. F., Li, H., Liu, W., Zhang, Y., Li, B., Qian, W., Wang, H., Chen, J., & Guo, Y. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.112 · Cited by 97
Yang, Z., Yu, B., Zhu, J., Huang, X., Xie, J., Xu, S., Yang, X., Wang, X., Yung, B. C., Lee, L. J., et al. (2014) · Nanoscale · doi:10.1039/c4nr01510j · Cited by 95
Stuart, D. D., Kao, G. Y., & Allen, T. M. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700145 · Cited by 92
Lipid nanoparticles silence tumor necrosis factor α to improve wound healing in diabetic mice
Kasiewicz, L. N., & Whitehead, K. A. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10123 · Cited by 86
Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery
Tagalakis, A. D., Lee, D. D. H., Bienemann, A. S., Zhou, H., Munye, M. M., Saraiva, L., McCarthy, D., Du, Z., Vink, C. A., Maeshima, R., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.003 · Cited by 85
Akita, H., Ishiba, R., Hatakeyama, H., Tanaka, H., Sato, Y., Tange, K., Arai, M., Kubo, K., & Harashima, H. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201200431 · Cited by 84
Nakamura, T., Kuroi, M., Fujiwara, Y., Warashina, S., Sato, Y., & Harashima, H. (2016) · Scientific Reports · doi:10.1038/srep37849 · Cited by 83
Microfluidic self-assembly of folate-targeted monomolecular siRNA-lipid nanoparticles
Krzysztoń, R., Salem, B., Lee, D.-J., Schwake, G., Wagner, E., & Rädler, J. O. (2017) · Nanoscale · doi:10.1039/c7nr01593c · Cited by 83
Heiati, H., Phillips, N. C., & TAWASHI, R. (1996) · Pharmaceutical Research · doi:10.1023/a:1016090420759 · Cited by 82
Akita, H., Ishiba, R., Togashi, R., Tange, K., Nakai, Y., Hatakeyama, H., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.029 · Cited by 80
Yamamoto, Y., Lin, P. J. C., Beraldi, E., Zhang, F., Kawai, Y., Leong, J., Katsumi, H., Fazli, L., Fraser, R., Cullis, P. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0866 · Cited by 79
Okamoto, A., Asai, T., Hirai, Y., Shimizu, K., Koide, H., Minamino, T., & Oku, N. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01055 · Cited by 79
Self-citationKong, W. H., Park, K., Lee, M. Y., Lee, H., Sung, D. K., & Hahn, S. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.067 · Cited by 77
Tadin‐Strapps, M., Peterson, L. B., Cumiskey, A.-M., Rosa, R. L., Mendoza, V., Castro‐Perez, J. M., Puig, Ó., Zhang, L., Strapps, W. R., Yendluri, S., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012872 · Cited by 77
Nanotechnology: A magic bullet for HIV AIDS treatment
Kumar, L., Verma, S., Prasad, D. N., Bhardwaj, A., Vaidya, B., & Jain, A. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.883400 · Cited by 76
Zhao, Y., Gao, H., He, J., Jiang, C., Lu, J., Zhang, W., Yang, H., & Liu, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.041 · Cited by 75
Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK
Paolo, D. D., Brignole, C., Pastorino, F., Carosio, R., Zorzoli, A., Rossi, M., Loi, M., Pagnan, G., Emionite, L., Cilli, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.54 · Cited by 74
Recent trends on hydrogel based drug delivery systems for infectious diseases
Vashist, A., Kaushik, A. K., Vashist, A., Jayant, R. D., Tomitaka, A., Ahmad, S., Gupta, Y. K., & Nair, M. (2016) · Biomaterials Science · doi:10.1039/c6bm00276e · Cited by 74
Song, P., Yang, C., Thomsen, J. S., Dagnæs‐Hansen, F., Jakobsen, M., Brüel, A., Deleuran, B. W., & Kjems, J. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.002 · Cited by 74
Yang, Z., Liu, T., Xie, Y., Sun, Z., Liu, H., Lin, J., Liu, C., Mao, Z., & Nie, S. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.07.026 · Cited by 73
Yu, B., Wang, X., Zhou, C., Teng, L., Ren, W., Yang, Z., Shih, C., Wang, T., Lee, R. J., Tang, S.-Q., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1366-7 · Cited by 73
Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 72
Yamamoto, N., Sato, Y., Munakata, T., Kakuni, M., Tateno, C., Sanada, T., Hirata, Y., Murakami, S., Tanaka, Y., Chayama, K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.014 · Cited by 67
Paolo, D. D., Ambrogio, C., Pastorino, F., Brignole, C., Martinengo, C., Carosio, R., Loi, M., Pagnan, G., Emionite, L., Cilli, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.142 · Cited by 64
Shen, J., Liu, H., Mu, C., Wolfram, J., Zhang, W., Kim, H.-C., Zhu, G., Hu, Z., Ji, L.-N., Liu, X., et al. (2017) · Nanoscale · doi:10.1039/c7nr00377c · Cited by 63
Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo
Lee, S., Yang, S. C., Kao, C., Pierce, R. H., & Murthy, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp758 · Cited by 62
Nakamura, T., Yamada, K., Fujiwara, Y., Sato, Y., & Harashima, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01166 · Cited by 61
Suzuki, Y., & Ishihara, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.124 · Cited by 60
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA
Thi, E. P., Lee, A. C. H., Geisbert, J. B., Ursic-Bedoya, R. J., Agans, K. N., Robbins, M., Deer, D. J., Fenton, K. A., Kondratowicz, A. S., MacLachlan, I., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.142 · Cited by 58
Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide
Li, Y., Lee, R. J., Yu, K., Bi, Y., Qi, Y., Sun, Y., Li, Y., Xie, J., & Teng, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b09991 · Cited by 58
Biodegradable Nanoparticles With Sustained Release of Functional siRNA in Skin
Jacobson, G. B., González-González, E., Spitler, R., Shinde, R., Leake, D., Kaspar, R. L., Contag, C. H., & Zare, R. N. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22147 · Cited by 55
Akita, H., Noguchi, Y., Hatakeyama, H., Sato, Y., Tange, K., Nakai, Y., & Harashima, H. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00203 · Cited by 55
Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion
Nir, S., Nicol, F., & Szoka, F. C. (1999) · Molecular Membrane Biology · doi:10.1080/096876899294814 · Cited by 54
Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy
Adesina, S. K., & Akala, E. O. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00335 · Cited by 53
Yotsumoto, F., Oki, E., Tokunaga, E., Maehara, Y., Kuroki, M., & Miyamoto, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25472 · Cited by 51
Wang, H., Tam, Y. Y. C., Chen, S., Zaifman, J., van der Meel, R., Ciufolini, M. A., & Cullis, P. R. (2016) · Molecular Therapy · doi:10.1038/mt.2016.179 · Cited by 50
Cressman, S., Dobson, I., Lee, J. B., Tam, Y. Y. C., & Cullis, P. R. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900041f · Cited by 47
Podesta, J. E., & Kostarelos, K. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)64017-9 · Cited by 45
Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications
Suter, S. R., Ball‐Jones, A. A., Mumbleau, M. M., Valenzuela, R., Ibarra‐Soza, J. M., Owens, H., Fisher, A. J., & Beal, P. A. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02654d · Cited by 42
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
Thi, E. P., Mire, C. E., Lee, A. C. H., Geisbert, J. B., Ursic-Bedoya, R. J., Agans, K. N., Robbins, M., Deer, D. J., Cross, R. W., Kondratowicz, A. S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci96185 · Cited by 41
Sakurai, Y., Mizumura, W., Murata, M., Hada, T., Yamamoto, S., Ito, K., Iwasaki, K., Katoh, T., Goto, Y., Takagi, A., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00362 · Cited by 40
Tanaka, H., Akita, H., Ishiba, R., Tange, K., Arai, M., Kubo, K., & Harashima, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.016 · Cited by 39
Alagia, A., Jorge, A. F., Aviñó, A. M., Cova, T. F. G. G., Crehuet, R., Grijalvo, S., Pais, A. A. C. C., & Eritja, R. (2018) · Chemical Science · doi:10.1039/c8sc00010g · Cited by 39
Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination
Glass, J. J., Kent, S. J., & Rose, R. D. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1141054 · Cited by 35
Duan, L., Yan, Y., Liu, J., Wang, B., Li, P., Hu, Q., & Chen, W. (2016) · Scientific Reports · doi:10.1038/srep24867 · Cited by 35
Terrazas, M., Ocampo, S. M., Perales, J. C., Márquez, V. E., & Eritja, R. (2011) · ChemBioChem · doi:10.1002/cbic.201000791 · Cited by 32
Moon, J.-S., Lee, S., Han, S.-H., Kim, E., Cho, H., Lee, W., Kim, M. K., Kim, T.-E., Park, H., Rhee, J., et al. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.02.015 · Cited by 32
Targeting a Monocyte Subset to Reduce Inflammation
Gordon, S. (2012) · Circulation Research · doi:10.1161/res.0b013e31825ec26d · Cited by 31
Akita, H., Nakatani, T., Kuroki, K., Maenaka, K., Tange, K., Nakai, Y., & Harashima, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.043 · Cited by 30
Toriyabe, N., Sakurai, Y., Kato, A., Yamamoto, S., Tange, K., Nakai, Y., Akita, H., & Harahsima, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.042 · Cited by 29
Tanaka, H., Watanabe, A., Konishi, M., Nakai, Y., Yoshioka, H., Ohkawara, T., Takeda, H., Harashima, H., & Akita, H. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00959 · Cited by 28
Berger, E., Breznan, D., Stals, S., Jasinghe, V. J., Gonçalves, D., Girard, D., Faucher, S., Vincent, R., Thierry, A. R., & Lavigne, C. (2017) · Nanobiomedicine · doi:10.1177/1849543517746259 · Cited by 27
Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma
Knapp, C. M., He, J., LISTER, J. W., & Whitehead, K. A. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10088 · Cited by 24
Nanotechnology applications to HIV vaccines and microbicides
Mohapatra, S. S., Boyapalle, S., & Mohapatra, S. (2012) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.93764 · Cited by 23
Cited by
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
Kumar, S., Duan, Q., Wu, R., Harris, E. N., & Su, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113869 · Cited by 351
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Metadata
- Authors
- Yonezawa, S., Koide, H., & Asai, T.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 154-155
- Pages
- 64-78
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3047437072
- Cited by
- 378
- References
- 206
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.